Which Tissues Are More Vulnerable?
The Clinical Meaning of Radiosensitivity
Radiation does not affect every tissue in the human body in the same way.
Some cells are damaged or eliminated relatively easily after ionizing radiation exposure, whereas others can tolerate substantial radiation injury before clinically apparent dysfunction develops. This difference is known as radiosensitivity and is one of the fundamental concepts of radiation biology.
The classical explanation is the Bergonie–Tribondeau law, which states that cells tend to be more radiosensitive when they divide frequently and remain relatively undifferentiated. In general, highly proliferative cell populations are more vulnerable because radiation-induced DNA damage becomes particularly consequential when cells attempt to replicate or divide.
However, radiosensitivity is not determined by proliferation alone. DNA repair capacity, cell-cycle phase, tissue architecture, stem-cell organization, vascular response, oxygenation, radiation dose, dose rate, fractionation, irradiated volume, and individual biological variation all influence the final tissue response.
This distinction is clinically important because the same radiation dose can have very different consequences depending on which tissue receives it, how much tissue is exposed, and how the dose is delivered.
1. The Bergonie–Tribondeau Law: Why Do Some Cells Die More Easily?
The Bergonie–Tribondeau principle remains a useful starting point for understanding radiosensitivity.
It can be summarized as follows:
Cells that divide frequently tend to be more radiosensitive.
Less differentiated cells tend to be more radiosensitive.
Cells with a long proliferative life and a high requirement for regeneration are particularly vulnerable.
Terminally differentiated, slowly proliferating cells generally show greater cellular radioresistance.
Historically, this principle helped explain why tissues containing rapidly proliferating stem and progenitor cells are particularly sensitive to radiation. Bone marrow and gastrointestinal epithelium are classic examples.
Figure 1. Bergonie–Tribondeau principle of cellular radiosensitivity.
The important point is that the law is a general biological principle rather than an absolute rule.
Lymphocytes illustrate this limitation particularly well. Although many lymphocytes are not continuously undergoing rapid mitosis, they are extremely radiosensitive. Their response reflects mechanisms beyond simple proliferative rate, including their cellular response to DNA damage.
Therefore, it is more accurate to say:
Proliferation strongly influences radiosensitivity, but it does not completely determine it.
2. Which Tissues Are Most Radiosensitive?
A classical classification places rapidly renewing tissues near the high-sensitivity end and slowly proliferating tissues near the radioresistant end.
Figure 2. Relative radiosensitivity of major tissues and cell populations.
High radiosensitivity
Important highly radiosensitive cell populations include:
Lymphocytes
Hematopoietic stem and progenitor cells
Intestinal crypt cells
Spermatogonia
Certain ovarian follicular cell populations
Other rapidly renewing epithelial populations
The bone marrow is particularly important because blood-cell production depends on a continuously renewing population of hematopoietic stem and progenitor cells. Significant radiation injury to these populations can therefore produce cytopenias and, at sufficiently high whole-body exposures, hematopoietic radiation syndrome.
The gastrointestinal tract is another classic example. The intestinal epithelium is continuously renewed from proliferative cells located in the crypts. Severe depletion of these cells can impair mucosal regeneration and produce substantial gastrointestinal toxicity.
Intermediate-to-high radiosensitivity
Skin and mucosal surfaces contain continuously renewing epithelial populations and therefore show clinically relevant radiation responses.
Depending on the dose and fractionation schedule, radiation exposure can produce:
Erythema
Epilation
Dry or moist desquamation
Mucosal inflammation
Impaired epithelial regeneration
These effects are particularly relevant during radiotherapy because the skin and mucosa may lie directly within or near the treatment field.
Relatively low cellular radiosensitivity
Mature muscle and many mature neural cells are generally more resistant at the cellular level because they are highly differentiated and divide infrequently.
However, radioresistance does not mean radiation-proof.
Slowly proliferating tissues may demonstrate relatively little early injury while developing clinically important delayed effects after sufficient exposure. Vascular injury, fibrosis, tissue remodeling, and progressive loss of functional reserve can contribute to late radiation toxicity.
3. Radiosensitivity Is Not the Same as Organ Radiation Tolerance
One of the most important clinical distinctions is the difference between cellular radiosensitivity and organ tolerance.
A tissue may contain relatively resistant cells but still be clinically vulnerable because the organ depends on a specialized architecture or a small population of critical supporting cells.
Conversely, an organ may contain radiosensitive cells but retain considerable functional reserve after a limited volume has been irradiated.
This is why modern radiation oncology does not simply ask:
“How radiosensitive is this organ?”
Instead, clinicians consider a much broader set of variables:
Cell type → dose → fractionation → irradiated volume → tissue architecture → functional reserve → vascular response → clinical endpoint
Figure 3. From cellular radiosensitivity to clinical tissue injury.
The volume of tissue exposed can be particularly important. Modern radiotherapy therefore uses dose-volume information rather than relying on a single radiation dose value. The same dose may have very different clinical consequences when delivered to a small versus a large portion of an organ.
4. Acute-Responding and Late-Responding Tissues
Another useful clinical distinction is between early-responding tissues and late-responding tissues.
Rapidly renewing tissues tend to develop radiation effects relatively quickly because their function depends on continuous replacement of cells.
Examples include:
Bone marrow
Intestinal epithelium
Skin
Oral and gastrointestinal mucosa
These tissues can show toxicity during or shortly after a course of radiotherapy.
By contrast, slowly proliferating tissues may show relatively little immediate injury but develop delayed consequences months or years later.
Examples include:
Central nervous system structures
Some connective tissues
Certain vascular structures
Other slowly renewing tissues
Figure 4. Early versus late radiation tissue responses.
This distinction has direct implications for radiation therapy planning.
A patient may complete treatment without severe acute toxicity but still require long-term monitoring for late effects. Conversely, acute mucosal or skin toxicity may be prominent during treatment but recover substantially after the proliferative cell population is restored.
5. The Special Case of Lymphocytes
Lymphocytes deserve separate attention.
They are among the most radiation-sensitive cells in the human body, despite the fact that their radiosensitivity cannot be explained simply by rapid proliferation.
This is clinically important in both radiation exposure and radiation therapy.
A substantial reduction in circulating lymphocytes can occur after radiation exposure, and lymphocyte dynamics have become increasingly relevant to the interaction between radiation, immunity, and cancer treatment.
Figure 5. Why lymphocytes are exceptionally radiosensitive.
This example demonstrates why the Bergonie–Tribondeau law should be interpreted as a framework rather than a rigid predictive formula.
6. Why Does Radiation Therapy Depend on Radiosensitivity?
The fundamental challenge of radiotherapy can be expressed in one sentence:
Destroy the tumor while preserving the normal tissues surrounding it.
Tumor cells are not automatically more radiosensitive than every normal cell.
Some cancers are highly responsive to radiation, whereas others show substantial radioresistance. Tumor hypoxia, DNA repair capacity, cell-cycle distribution, genomic alterations, tumor microenvironment, and repopulation can all influence treatment response.
At the same time, normal tissues surrounding the tumor have their own radiation tolerances.
Therefore, radiation oncology is essentially an optimization problem:
Tumor control probability ↑
while simultaneously maintaining
Normal tissue complication probability ↓
Figure 6. The therapeutic window in radiation oncology.
The success of radiotherapy therefore depends not simply on delivering a high dose, but on creating a favorable therapeutic ratio.
Normal tissue tolerance limits the dose that can safely be delivered to the tumor. This is why radiation treatment planning has evolved from simple geometric field arrangements to highly conformal, image-guided, intensity-modulated, stereotactic, and adaptive approaches.
7. Fractionation Changes the Biological Equation
Radiation dose is not the only variable.
The way that dose is divided into fractions can substantially influence the balance between tumor control and normal tissue toxicity.
Fractionation allows normal tissues with different repair characteristics to recover between radiation exposures while maintaining therapeutic effects against tumor cells.
This principle is one reason why a total radiation dose cannot be interpreted without knowing:
Number of fractions
Dose per fraction
Overall treatment time
Treatment volume
Tissue-specific response
Dose distribution
Figure 7. Why fractionation matters.
This is also why comparing radiation doses between different treatment techniques without considering fractionation can be misleading.
8. The Modern View: Radiosensitivity Is a Network Property
The traditional classification of tissues into “sensitive” and “resistant” remains useful for teaching, but modern radiation biology recognizes a much more complex system.
Radiosensitivity is influenced by multiple interacting factors:
| Factor | Influence on Radiation Response |
|---|---|
| Cell proliferation | Rapidly dividing populations are generally more vulnerable |
| Differentiation | Less differentiated cells tend to be more radiosensitive |
| DNA repair | Efficient repair can increase cellular survival |
| Cell-cycle phase | Radiosensitivity varies throughout the cell cycle |
| Oxygenation | Oxygen can enhance radiation-induced DNA damage |
| Stem-cell reserve | Determines tissue regeneration after injury |
| Tissue architecture | Determines how cellular loss translates into organ dysfunction |
| Dose per fraction | Influences biological effect |
| Irradiated volume | Strongly affects normal-tissue complication risk |
| Individual biology | Patients can differ substantially in normal-tissue response |
This explains why two patients receiving apparently similar treatments may not experience identical toxicity.
Individual variation in normal-tissue response has been documented, and research continues into biological markers that might eventually help predict radiation sensitivity before treatment.
9. Radiosensitivity and Medical Imaging
Radiology and medical imaging are closely connected to the concept of radiosensitivity.
Diagnostic imaging generally uses substantially lower radiation doses than therapeutic radiation, but the principle of dose optimization remains fundamental.
For examinations involving ionizing radiation, such as:
CT
CT angiography
Fluoroscopy
Interventional radiology
Nuclear medicine
the objective is not simply to minimize radiation at all costs.
The goal is to obtain the necessary diagnostic information with an appropriately optimized radiation exposure.
This is particularly important for:
Children
Young adults
Patients requiring repeated examinations
Patients undergoing image-guided procedures
Patients with potentially radiosensitive tissues within the exposure field
Modern imaging technology increasingly incorporates automated exposure control, iterative or model-based reconstruction, protocol optimization, and artificial intelligence-assisted image reconstruction or denoising to maintain diagnostic quality while managing radiation exposure.
Thus, the concept of radiosensitivity provides a biological foundation for the clinical principle of justification and optimization.
10. Why “Radiation Sensitive” Does Not Mean “Always Dangerous”
A common misunderstanding is to interpret tissue radiosensitivity as an absolute ranking of danger.
That interpretation is incorrect.
A highly radiosensitive tissue may receive a very small dose and experience no clinically significant injury.
Conversely, a relatively radioresistant tissue can develop severe injury if exposed to a sufficiently high dose, particularly when a critical structure or large tissue volume is involved.
The clinical question is therefore not:
“Is this tissue radiosensitive?”
but rather:
“How much radiation reached this tissue, in what pattern, over what time period, and what biological function depends on the irradiated cells?”
This distinction is essential for interpreting radiation exposure in both diagnostic imaging and radiation oncology.
11. The Clinical Meaning of Radiosensitivity
The practical significance of radiosensitivity can be summarized in four levels.
Level 1 — Cellular biology
Radiation causes DNA damage.
Cells differ in their ability to repair that damage and maintain reproductive integrity.
Level 2 — Tissue biology
Loss of radiosensitive cell populations can impair regeneration.
The clinical manifestation depends on how rapidly the tissue normally replaces its cells.
Level 3 — Organ function
Radiation injury to a tissue does not necessarily translate directly into immediate organ failure.
Organ architecture, functional reserve, vascular supply, and irradiated volume all matter.
Level 4 — Clinical treatment
Radiation oncologists must maximize tumor control while limiting normal tissue injury.
This creates the therapeutic window within which radiotherapy can be safely delivered.
Figure 8. The clinical pathway from radiosensitivity to treatment decision.
12. The Most Important Insight
The most important lesson is not simply that bone marrow is sensitive and muscle is resistant.
The deeper principle is this:
Radiation sensitivity is a biological property, whereas radiation toxicity is a clinical outcome.
The two are related, but they are not identical.
A tissue's clinical response depends on the interaction of cellular radiosensitivity with dose, fractionation, volume, tissue organization, repair capacity, vascular effects, and individual susceptibility.
For cancer treatment, this leads to the central objective of radiation oncology:
Kill the tumor cells while preserving the normal tissues that the patient needs to survive and function.
Figure 9. The therapeutic balance of radiation.
Key Takeaways
The Bergonie–Tribondeau law provides a classical framework for understanding radiosensitivity.
Rapidly proliferating and relatively undifferentiated cells are generally more radiosensitive.
Bone marrow, lymphocytes, intestinal epithelium, and germ-cell populations are among the clinically important radiosensitive populations.
Skin and mucosa can develop significant radiation reactions because of their continuous cellular renewal.
Mature muscle and many mature neural cells are relatively radioresistant at the cellular level, but they are not immune to radiation injury.
Cellular radiosensitivity should not be confused with whole-organ radiation tolerance.
Dose, fractionation, irradiated volume, tissue architecture, oxygenation, DNA repair, and individual biological variation all influence clinical radiation effects.
In radiotherapy, the key objective is to maximize tumor control while maintaining an acceptable probability of normal tissue injury.
In diagnostic imaging, radiosensitivity reinforces the importance of appropriate justification and dose optimization.
Modern radiation medicine increasingly treats radiosensitivity as a multifactorial biological property rather than a simple ranking of tissues.
Conclusion
The question “Which tissue is more vulnerable to radiation?” appears simple, but the biological answer is considerably more complex.
The classical Bergonie–Tribondeau law correctly captures an important principle: rapidly dividing, relatively undifferentiated cells tend to be more vulnerable to ionizing radiation. Yet modern radiation biology has shown that proliferation is only one component of the equation.
DNA repair capacity, cell-cycle state, oxygenation, stem-cell reserve, vascular effects, tissue architecture, dose fractionation, irradiated volume, and individual susceptibility can all modify the final outcome.
For clinicians, this distinction matters enormously.
Radiation treatment is not simply a matter of delivering enough radiation to destroy abnormal cells. It is a problem of biological selectivity—creating sufficient injury in the tumor while preserving the normal tissues that surround it.
That is the clinical meaning of radiosensitivity.
Radiation does not simply ask, “How much dose was delivered?”
It asks, “Which cells received it, how did they respond, and what function depends on them?”
References
National Research Council. Toxicological Profile for Ionizing Radiation. Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services.
Stewart FA, Akleyev AV, Hauer-Jensen M, et al. ICRP Publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs—threshold doses for tissue reactions in a radiation protection context. Ann ICRP. 2012;41(1–2):1–322. doi:10.1016/j.icrp.2012.02.001.
Burnet NG, Wurm R, Nyman J, Peacock JH. Normal tissue radiosensitivity—how important is it? Clin Oncol (R Coll Radiol). 1996;8(1):25–34. doi:10.1016/S0936-6555(05)80035-4.
Burnet NG, Johansen J, Turesson I, Nyman J, Peacock JH. Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Int J Cancer. 1998;79(6):606–613. doi:10.1002/(SICI)1097-0215(19981218)79:6<606::AID-IJC9>3.0.CO;2-Y.
Milano MT, Constine LS, Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol. 2007;17(2):131–140. doi:10.1016/j.semradonc.2006.11.009.
Withers HR, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys. 1988;14(4):751–759. doi:10.1016/0360-3016(88)90098-3.
Cohen L, Creditor M. Iso-effect tables for tolerance of irradiated normal human tissues. Int J Radiat Oncol Biol Phys. 1983;9(2):233–241. doi:10.1016/0360-3016(83)90105-0.
International Atomic Energy Agency. Radiation Biology: A Handbook for Teachers and Students. IAEA, Vienna.
International Atomic Energy Agency. Cytogenetic Dosimetry: Applications in Preparedness and Response to Radiation Emergencies. IAEA.
댓글
댓글 쓰기